MedTrace Logo

A Study of DF6002 Alone and in Combination With Nivolumab

NCT04423029 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.

Conditions

Interventions

DRUG

DF6002

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Sponsors & Collaborators

  • Dragonfly Therapeutics

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Dragonfly Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-13
Primary Completion
2025-11-26
Completion
2025-11-26
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04423029 on ClinicalTrials.gov